Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RXRB | P28702 | 2/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CD74 | P04233 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599273 | 0.85 | NR1H4 (0.60) | — | |
| SCHEMBL11227165 | 0.84 | KMO (0.72) | KMOCA12CA1CA2CA6 | |
| SCHEMBL28298835 | 0.82 | KMO (0.55) | KMOCA12CA1CA2CA6 | |
| SCHEMBL18788839 | 0.81 | KMO (0.68) | KMOCA12CA1CA2CA6 | |
| SCHEMBL28679980 | 0.80 | CA12 (0.56) | CA12CA1CA2CA6CA9 | |
| SCHEMBL4171236 | 0.80 | ALOX5 (0.60) | KMOCA12CA1CA2CA6 | |
| SCHEMBL30725957 | 0.80 | KMO (0.86) | KMOCA12CA1CA2CA6 | |
| SCHEMBL29904709 | 0.80 | KMO (0.86) | KMOCA12CA1CA2CA6 | |
| SCHEMBL71238 | 0.80 | KMO (0.86) | KMOCA12CA1CA2CA6 | |
| SCHEMBL4249787 | 0.79 | CA12 (0.76) | KMOCA12CA1CA2CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1937237-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | Revotar Biopharmaceuticals AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | SELP, SELL, SELE | KMO 3178/4885CA12 3746/4885CA1 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.